Modality
mRNA
MOA
Cl18.2
Target
PD-1
Pathway
STING
Crohn'sCF
Development Pipeline
Preclinical
~Jun 2019
→ ~Sep 2020
Phase 1
Dec 2020
→ Aug 2025
Phase 1Current
NCT06412867
2,020 pts·Crohn's
2020-12→2025-08·Recruiting
2,020 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-08-157mo agoPh2 Data· Crohn's
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P1/2
Recruit…
Catalysts
Ph2 Data
2025-08-15 · 7mo ago
Crohn's
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06412867 | Phase 1/2 | Crohn's | Recruiting | 2020 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 | |
| Tiratapinarof | Intellia | NDA/BLA | APOC3 |